Illumina Inc
XMUN:ILU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Illumina Inc
XMUN:ILU
|
US |
|
B
|
Bank Central Asia Tbk PT
SWB:BZG2
|
ID |
|
Asia Vital Components Co Ltd
OTC:AVMPF
|
TW |
|
Aeon Co Ltd
OTC:AONNF
|
JP |
|
A
|
Abb Ltd
XBER:ABJ
|
CH |
|
Orange SA
BMV:ORANN
|
FR |
Illumina Inc
Illumina makes DNA sequencing systems and the consumables that run on them. Its machines read genetic code, and its test kits and reagents are used to prepare samples and generate sequencing data. The company mainly sells to hospitals, research labs, biotech companies, and clinical testing groups that need to analyze DNA for science or diagnosis. Illumina makes money in two main ways: it sells sequencing instruments and, more importantly, it sells the recurring chemicals and kits used every time those systems are run. That gives the business a mix of upfront equipment sales and repeat consumable revenue. Once a lab installs Illumina equipment, it often keeps buying compatible reagents and service support to keep its workflows running. What makes Illumina different is that it sits at the center of the genomics workflow. It does not usually run the tests itself; instead, it supplies the tools that let others do the testing and analysis. That makes it a key picks-and-shovels company in genetic research and molecular diagnostics, with customers relying on its technology as the starting point for many DNA-based applications.
Illumina makes DNA sequencing systems and the consumables that run on them. Its machines read genetic code, and its test kits and reagents are used to prepare samples and generate sequencing data. The company mainly sells to hospitals, research labs, biotech companies, and clinical testing groups that need to analyze DNA for science or diagnosis.
Illumina makes money in two main ways: it sells sequencing instruments and, more importantly, it sells the recurring chemicals and kits used every time those systems are run. That gives the business a mix of upfront equipment sales and repeat consumable revenue. Once a lab installs Illumina equipment, it often keeps buying compatible reagents and service support to keep its workflows running.
What makes Illumina different is that it sits at the center of the genomics workflow. It does not usually run the tests itself; instead, it supplies the tools that let others do the testing and analysis. That makes it a key picks-and-shovels company in genetic research and molecular diagnostics, with customers relying on its technology as the starting point for many DNA-based applications.
Beat and raise: Illumina said Q1 revenue, margin, and EPS all came in above guidance, and it raised full-year revenue, operating margin, and EPS outlooks.
Clinical strength: Clinical demand remained the main growth engine, with clinical sequencing consumables up 20% ex China for the second straight quarter and clinical now more than 65% of sequencing consumables revenue.
NovaSeq X demand: NovaSeq X placements were very strong at more than 80 units in Q1, and management said the business was supply constrained and sees robust demand into Q2 and the back half of the year.
Research cautious: Research and applied markets remained soft because of funding uncertainty, and management did not build much near-term recovery into guidance, though it sees upside if the environment improves.
Margin bridge: Q2 margins will be pressured by instrument mix, freight and component inflation, and a full quarter of SomaLogic, but management expects mitigation actions to show through in the second half.
Innovation focus: Illumina highlighted TruPath, spatial transcriptomics, BioInsight, and the 18-month NovaSeq X roadmap as key parts of its growth strategy and future platform expansion.
